- Home
- SQFT vs SNGX Comparison
SQFT vs SNGX Comparison
Compare SQFT & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- SNGX
- Stock Information
- Founded
- SQFT 1999
- SNGX 1987
- Country
- SQFT United States
- SNGX United States
- Employees
- SQFT N/A
- SNGX N/A
- Industry
- SQFT Real Estate Investment Trusts
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SQFT Real Estate
- SNGX Health Care
- Exchange
- SQFT Nasdaq
- SNGX Nasdaq
- Market Cap
- SQFT 6.2M
- SNGX 6.5M
- IPO Year
- SQFT 2020
- SNGX 1987
- Fundamental
- Price
- SQFT $4.62
- SNGX $1.37
- Analyst Decision
- SQFT
- SNGX
- Analyst Count
- SQFT 0
- SNGX 0
- Target Price
- SQFT N/A
- SNGX N/A
- AVG Volume (30 Days)
- SQFT 5.0K
- SNGX 147.3K
- Earning Date
- SQFT 08-13-2025
- SNGX 08-08-2025
- Dividend Yield
- SQFT N/A
- SNGX N/A
- EPS Growth
- SQFT N/A
- SNGX N/A
- EPS
- SQFT N/A
- SNGX N/A
- Revenue
- SQFT $18,260,398.00
- SNGX $2,342.00
- Revenue This Year
- SQFT $23.63
- SNGX N/A
- Revenue Next Year
- SQFT N/A
- SNGX N/A
- P/E Ratio
- SQFT N/A
- SNGX N/A
- Revenue Growth
- SQFT N/A
- SNGX N/A
- 52 Week Low
- SQFT $4.19
- SNGX $1.31
- 52 Week High
- SQFT $8.77
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- SQFT 34.89
- SNGX 23.71
- Support Level
- SQFT $4.19
- SNGX $1.31
- Resistance Level
- SQFT $4.57
- SNGX $1.95
- Average True Range (ATR)
- SQFT 0.19
- SNGX 0.07
- MACD
- SQFT 0.01
- SNGX -0.05
- Stochastic Oscillator
- SQFT 30.65
- SNGX 9.56
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).